Gilead Sciences (NASDAQ:GILD) Releases Quarterly Earnings Results, Beats Expectations By $0.51 EPS

Gilead Sciences (NASDAQ:GILD) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.26) by $0.51, Zacks reports. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period last year, the company posted $2.01 earnings per share. Gilead Sciences updated its FY 2026 guidance to -0.650–0.300 EPS.

Here are the key takeaways from Gilead Sciences’ conference call:

• Base business sales rose 10% year over year to $7.6 billion, prompting Gilead to raise its 2026 base-business sales outlook to $29.8 billion–$30.1 billion and total product sales outlook to $30.1 billion–$30.4 billion.
• HIV sales grew 12%, with quarterly PrEP revenue exceeding $1 billion for the first time and Yeztugo achieving more than 70% six-month reinjection persistence. Gilead raised its full-year HIV growth forecast to 9%–10% and continues to expect approximately $1 billion in 2026 Yeztugo sales.
• Trodelvy sales increased 26% to $457 million, supported by demand in breast cancer and new first-line metastatic triple-negative breast cancer approvals. Livdelzi sales more than doubled to $167 million, while positive IDEAL results could expand its PBC opportunity.
• The company highlighted several potential growth catalysts, including an expected August FDA decision for once-daily BIC/LEN, a potential 2027 launch for once-weekly oral HIV treatment, and a December 23 FDA decision for anito-cel in multiple myeloma.
• Cell therapy sales fell 14% year over year to $417 million amid competitive pressure, particularly for Tecartus. Acquisitions of Arcellx, Tubulis, and Ouro generated approximately $11.2 billion in acquired IPR&D expenses, driving reported non-GAAP EPS to negative $6.75 and full-year EPS guidance to negative $0.65–negative $0.30.

Gilead Sciences Stock Up 3.1%

Shares of Gilead Sciences stock traded up $4.10 during trading hours on Tuesday, reaching $135.25. The company’s stock had a trading volume of 10,084,002 shares, compared to its average volume of 6,430,147. The company has a market capitalization of $167.92 billion, a P/E ratio of 18.43 and a beta of 0.32. The stock’s fifty day simple moving average is $129.58 and its two-hundred day simple moving average is $136.11. Gilead Sciences has a one year low of $108.46 and a one year high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported a quarterly loss of $6.75 per share, which was better than analysts’ expected loss of approximately $7.07–$7.26 per share. Product sales increased 8% year over year and exceeded Wall Street estimates, providing support for the shares. Gilead Sciences Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: HIV medicines delivered double-digit sales growth. Yeztugo, Gilead’s newer HIV pre-exposure prophylaxis drug, narrowly beat sales expectations, keeping attention on its potential to become a major long-term growth driver. Gilead’s High-Profile HIV Drug Beat
• Positive Sentiment: California’s highest court ruled in Gilead’s favor in a product-liability case, finding that drugmakers do not have a legal duty to develop an even safer alternative when an existing medicine is considered safe. The decision reduces a potentially significant legal risk. California Court Rules for Gilead
• Neutral Sentiment: Gilead posted a quarterly loss because of costs associated with recent acquisitions, although its underlying operating performance benefited from stronger HIV demand. Gilead Second-Quarter Sales Rise
• Negative Sentiment: Management lowered its full-year Veklury forecast after sales of the COVID-19 treatment plunged 81% in the quarter. This highlights continuing pressure on a legacy revenue stream. Gilead Swings to Loss on R&D Costs
• Negative Sentiment: Full-year revenue guidance of $30.1 billion to $30.4 billion is below the $30.5 billion analyst consensus, which may limit enthusiasm despite better-than-expected EPS guidance. AIDS Healthcare Foundation also criticized Gilead’s pricing and business practices, adding reputational pressure. AHF Crowns Gilead Corporate Welfare King

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the transaction, the insider owned 124,234 shares in the company, valued at approximately $15,395,077.28. The trade was a 2.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 82,000 shares of company stock valued at $10,641,790 over the last three months. Corporate insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its holdings in Gilead Sciences by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after acquiring an additional 1,195,269 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after acquiring an additional 3,046,688 shares in the last quarter. Amundi lifted its holdings in Gilead Sciences by 25.5% during the fourth quarter. Amundi now owns 9,520,135 shares of the biopharmaceutical company’s stock worth $1,168,501,000 after acquiring an additional 1,936,354 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Gilead Sciences by 1.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,006,790 shares of the biopharmaceutical company’s stock valued at $982,753,000 after purchasing an additional 75,930 shares during the last quarter. Finally, Raymond James Financial Inc. increased its position in shares of Gilead Sciences by 50.6% during the 4th quarter. Raymond James Financial Inc. now owns 2,734,917 shares of the biopharmaceutical company’s stock valued at $336,007,000 after purchasing an additional 919,106 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Gilead Sciences in a research note on Wednesday, July 29th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the company from $133.00 to $155.00 in a research note on Monday, July 6th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Finally, Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $157.93.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.